At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
botulinum toxin type A neurotoxin complex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Treatment of Depression With Botulinum Type A Toxin (Botox): A Randomized, Double Blind, Crossover Study
In Brief
A Phase 2 clinical trial evaluating botulinum toxin type A neurotoxin complex and Placebo for Depression. Completed, enrolled 30 participants across 1 site.
Detailed Summary
A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psychiatrist at every visit who will assess their depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionNov 2012
Study CompletionJun 2013
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartJul 1, 2011
Primary CompletionNov 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.0 years ago
Interventions
botulinum toxin type A neurotoxin complexdrug
29-40 U injection
Placebodrug
29-40 U 0.9% NaCl injection